
GPhA Supports Restricted Access Bill
GPhA throws its support behind a bill to prohibit companies from using REMS practices to deter competition.
The Generic Pharmaceutical Association has expressed its support of a
“This important bill introduced today by Congressmen Steve Stivers (R-OH) and Peter Welch (D-VT) promises to prevent unnecessary delays for patients waiting for generic choices and save billions for taxpayers, patients, and the federal government,” said Ralph G. Neas, president and CEO of GPhA, in a
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.